Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Case Report Volume 2 Issue 3

Decision to Use Rituximab as a Systemic Biological Treatment in Systemic Lupus Erythmatosus Among Sudanese Patients: Case Serious Report

Mohammed Elmujtba Adam Essa1*, Maha Elnigoumi2, Shaima N Elgenaid3*, Noha Ibrahim Ahmed Eltahir4, Ziryab Imad Taha Mahmoud1,5, Mustafa Mohamed Ali Hussein1, Mutwaly Defealla Yousif Haron1, Abdelkareem A Ahmed1,6* and Elnour Mohammed Elagib4

1Departments of Clinical Medicine, Medical and Cancer Research Institute (MCRI), Nyala, Sudan
2Department of Geriatric, Queen’s Medical Center, Nottingham University hospital, Nottingham, UK
3Faculty of Medicine, University of Khartoum, Khartoum, Sudan
4Department of Medicine and Rheumatology, Omdurman Military Hospital, Sudan
5Department of Internal Medicine, Faculty of Medicine, University of Bahri, Khartoum, Sudan
6Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Sudan
7Institute of Molecular Biology, University of Nyala, Nyala, Sudan

*Corresponding Author: Mohammed Elmujtba Adam Essa, Departments of Clinical Medicine, Medical and Cancer Research Institute (MCRI), Nyala, Sudan. E-mail: awadali818@yahoo.com; Abdelkareem Abdallah Ahmed, Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Nyala, Sudan E-mail: kareemo151@gmail.com; Shaima N Elgenaid, Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan, E-mail: shema2690@gmail.com

Received: December 03, 2019; Published: February 21, 2020

×

Abstract

 Systemic Lupus Erythematosus (SLE) is a disease with various manifestations. Its treatment aims to reduce the symptoms and to prevent the flairs. In this report, we are discussing three cases of SLE who required treatment with Rituximab. The first case was an 18 year old female who presented with urinary symptoms and subsequently she developed lupus nephritis. She was treated with prednisolone and hydroxychloroquine for two months without response. The Rituximab was introduced with a good initial response. The second case was a 20 year female, presented with nonspecific symptoms. She was treated with steroid but her condition was complicated by development of antiphospholipid antibodies, abortion and lupus nephritis. The last case also developed lupus nephritis despite the treatment with steroid and hydroxychloroquine. Rituximab was add but discontinued because the patient was financial unaffordable to provide the rest of the doses. Her condition deteriorated more and ultimately died.

Keywords: Biologic Treatment; Rituximab; Sudanese; Systemic Lupus Erythematosus

×

References

  1. Cojocaru M., et al. “Manifestations of systemic lupus erythematosus”. Maedica 6.4 (2011): 330.
  2. Manson J and Isenberg D. “The pathogenesis of systemic lupus erythematosus”. The Netherlands Journal of Medicine 61.33 (2003): 343-346.
  3. Casciola-Rosen LA., et al. “Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes”. Journal of Experimental Medicine 179.4 (1994): 1317-1330.
  4. He J and Li Z. “An era of biological treatment in systemic lupus erythematosus”. Springer (2018).
  5. Fanouriakis A., et al. “2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus”. Annals of the Rheumatic Diseases 78.6 (2019): 736-745.
  6. Mahmoud ZIT., et al. “The role of hydroxychloroquine as monotherapy in managing early undifferentiated arthritis: a prospective hospital-based study”. Global Journal of Public Health Medicine 1.2 (2019): 52-62.
  7. Ramos-Casals M., et al. “B-cell-depleting therapy in systemic lupus erythematosus”. The American Journal of Medicine 125.4 (2012): 327-336.
  8. CAlero I and Sanz I. “Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?” Discovery Medicine 10.54 (2010): 416.
  9. Postal M., et al. “Biological therapy in systemic lupus erythematosus”. International Journal of Rheumatology (2012).
  10. Merrill JT., et al. “Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial”. Arthritis and Rheumatism: Official Journal of the American College of Rheumatology 62.1 (2010): 222-233.
  11. Elagib E., et al. “Catastrophic Antiphospholipid Syndrome in Combination with SLE Treated by Rituximab: A Case Report and Literature Review”. Lupus: Open Access 4 (2019): 137.
  12. Arnaud L., et al. “Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study”. Autoimmunity reviews 13.11 (2014): 1082-1089.
  13. Somers EC., et al. “Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999”. Arthritis Care and Research 57.4 (2007): 612-618.
  14. Sasidharan P., et al. “Hematological manifestations of SLE at initial presentation: is it underestimated?” IS (2012).
  15. Wallace DJ. “Diagn RN hematology osis and differential diagnosis of systemic lupus erythematosus in adults”. UpToDate Waltham, MA: UpToDate (2017).
  16. Taraborelli M., et al. “The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus”. Lupus 25.12 (2016): 1365-1368.
  17. Boumpas DT., et al. “Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis”. The Lancet 340.8822 (1992): 741-745.
  18. Kalloo S., et al. “Lupus nephritis: treatment of resistant disease”. Clinical Journal of the American Society of Nephrology 8.1 (2013): 154-161.
×

Citation

Citation: Mohammed Elmujtba Adam Essa., et al. “Decision to Use Rituximab as a Systemic Biological Treatment in Systemic Lupus Erythmatosus Among Sudanese Patients: Case Serious Report”. Acta Scientific Women's Health 2.3 (2020): 01-06.




Member In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is April 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US